Immuron Limited Submits IND Application to FDA for IMM529 to Treat and Prevent Clostridioides difficile Infection
Immuron Limited has submitted an IND application to the FDA for IMM-529, aimed at treating and preventing Clostridioides difficile infection (CDI). The company plans to start a Phase 2 clinical trial in the first half of 2026, targeting patients with both first episode and recurrent CDI. No funding announcements were made. This news is generated by Public Technologies and is for informational purposes only.
Immuron Limited has announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its candidate IMM-529, targeting the prevention and treatment of Clostridioides difficile infection (CDI) and the prevention of recurrent CDI. The company plans to initiate a Phase 2 clinical trial in the first half of 2026, enrolling patients with both first episode and recurrent CDI. No grant or funding announcement involving multiple organizations was mentioned. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-097170), on October 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
